Log in
Enquire now
‌

Crosslife Technologies Inc. SBIR Phase II Award, January 2021

A SBIR Phase II contract was awarded to Crosslife Technologies Inc. in January, 2021 for $999,916.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2184749
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
Crosslife Technologies Inc.
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R44TR003549-010
Award Phase
Phase II0
Award Amount (USD)
999,9160
Date Awarded
January 15, 2021
0
End Date
December 31, 2022
0
Abstract

Point-of-Care Rapid RNA test for Zika CrossLife Technologies Inc. Project Summary/Abstract We aim to develop a rapid point-of-test that detects ZIKV at the point-of-need in andlt; 30 minutes and is appropriate for non-laboratory settings and non-technical personnel. Our proprietary test exploits a novel probe reaction chemistry that allows multiplexed detection of DNA or RNA without sample purification, making it operable as a simple, hand-held test. Patient samples to be input directly into the device without pre- processing and a disposable cartridge carry out amplification of all targets and reports visible results that can be read by eye. We have demonstrated the feasibility of a novel and simple detection of ZIKV using TARA (Templated Assisted Rapid Assay). The key goals of the Phase 2 project are to 1) develop and evaluate automated paper strip device and to 2) validate it using clinical samples. We will evaluate the automated paper strip device using 200 samples from a Navy-IRB approved protocol through our CRADA collaboration with U.S. Naval Medical Research Center and the U.S. Naval Medical Research Unit SIX. We expect a sensitivity (andgt;90%) and specificity (andgt;90%) to the qRT-PCR data on the same samples. The successful achievement of 1) time to result andlt; 30 min, 2) sensitivity andgt; 90%, specificity andgt; 90% and LOD andlt; 500 copies/test, 3) andgt; 90% user feedback on ease of use need for CLIA waiver, 4) requires no instrumentation, power source, or refrigeration of reagents, and 5) quantitative criteria for measuring the outcome of each task are exceeds or equivalent to the RT-PCR molecular test.Point-of-Care Rapid RNA test for Zika CrossLife Technologies, Inc. RESEARCH andamp; RELATED Other Project Information Narrative The rapid spread of Zika virus through the Americas, together with the connection of infection with microcephaly and Guillain-Barré syndrome, have driven this previously overlooked virus into the spotlight. The World Health Organization (WHO) predicts almost four million people could be infected with Zika virus in the Americas in the year 2016.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Crosslife Technologies Inc. SBIR Phase II Award, January 2021

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.